tetano
Editor, Senior Moderator
J Thromb Thrombolysis
. 2021 Oct 28.
doi: 10.1007/s11239-021-02597-y. Online ahead of print.
The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury
Giuseppe Lippi[SUP] 1 [/SUP], Ivan Szergyuk[SUP] 2 [/SUP], Maria Helena Santos de Oliveira[SUP] 3 [/SUP], Stefanie W Benoit[SUP] 4 5 [/SUP], Justin L Benoit[SUP] 6 [/SUP], Emmanuel J Favaloro[SUP] 7 [/SUP], Brandon Michael Henry[SUP] 8 9 [/SUP]
Affiliations
Abstract
Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes were measured in 50 COVID-19 patients and 30 matched sick controls. Lp(a) was also assessed for correlation with a wide panel of biomarkers. Serum Lp(a) did not significantly differ between COVID-19 patients and sick controls, though its concentration was found to be significantly associated with severity of COVID-19 illness, including acute kidney failure stage (r = 0.380, p = 0.007), admission disease severity (r = 0.355, p = 0.013), and peak severity (r = 0.314; p = 0.03). Lp(a) was also positively correlated with interleukin (IL)-8 (r = 0.308; p = 0.037), fibrinogen (r = 0.344; p = 0.032) and creatinine (r = 0.327; p = 0.027), and negatively correlated with ADAMTS13 activity/VWF:Ag (r = - 0.335; p = 0.021); but not with IL-6 (r = 0.241; p = 0.106). These results would hence suggest that adverse outcomes in patients with COVID-19 may be aggravated by a genetically determined hyper-Lp(a) state rather than any inflammation induced elevations.
Keywords: Acute kidney injury; Coagulopathy; Coronavirus disease 2019; Lipoprotein(a); Thrombosis.
. 2021 Oct 28.
doi: 10.1007/s11239-021-02597-y. Online ahead of print.
The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury
Giuseppe Lippi[SUP] 1 [/SUP], Ivan Szergyuk[SUP] 2 [/SUP], Maria Helena Santos de Oliveira[SUP] 3 [/SUP], Stefanie W Benoit[SUP] 4 5 [/SUP], Justin L Benoit[SUP] 6 [/SUP], Emmanuel J Favaloro[SUP] 7 [/SUP], Brandon Michael Henry[SUP] 8 9 [/SUP]
Affiliations
- PMID: 34709533
- DOI: 10.1007/s11239-021-02597-y
Abstract
Lipoprotein(a) (Lp(a)) is a prothrombotic and anti-fibrinolytic lipoprotein, whose role has not been clearly defined in the pathogenesis of coronavirus disease 2019 (COVID-19). In this prospective observational study, serum Lp(a) as well as outcomes were measured in 50 COVID-19 patients and 30 matched sick controls. Lp(a) was also assessed for correlation with a wide panel of biomarkers. Serum Lp(a) did not significantly differ between COVID-19 patients and sick controls, though its concentration was found to be significantly associated with severity of COVID-19 illness, including acute kidney failure stage (r = 0.380, p = 0.007), admission disease severity (r = 0.355, p = 0.013), and peak severity (r = 0.314; p = 0.03). Lp(a) was also positively correlated with interleukin (IL)-8 (r = 0.308; p = 0.037), fibrinogen (r = 0.344; p = 0.032) and creatinine (r = 0.327; p = 0.027), and negatively correlated with ADAMTS13 activity/VWF:Ag (r = - 0.335; p = 0.021); but not with IL-6 (r = 0.241; p = 0.106). These results would hence suggest that adverse outcomes in patients with COVID-19 may be aggravated by a genetically determined hyper-Lp(a) state rather than any inflammation induced elevations.
Keywords: Acute kidney injury; Coagulopathy; Coronavirus disease 2019; Lipoprotein(a); Thrombosis.